Table 1.

Main characteristics of the 42 patients included in this retrospective study of the effects of long-term treatment with pegvisomant on acromegalic comorbidities.

Number, n	42
Males/females	26/16
Age at diagnosis, years (range)	36 (15–64)
Macroadenoma, n (%)	40 (95)
Time between diagnosis of acromegaly and pegvisomant introduction (months)	55 (3–240)
Treatments prior to pegvisomant
Surgery, n	32
Radiotherapy, n	7
Somatostatin analogs, n	40
Cabergoline, n	21
Metabolic parameters at pegvisomant introduction
BMI (kg/m2), mean (range)	31 (21–41)
Diabetes, n (%)	10 (24)
Statin therapy, n (%)	2 (5)
Hypertension at pegvisomant introduction, n (%)	11 (26)
Mean IGF1 (% ULN) at pegvisomant introduction (range)	271 (94–633)
Treatment
Pegvisomant alone, n (%)	19 (45)
Pegvisomant plus other drugs, n (%)	23 (55)
Somatostatin analogs, n	15
Cabergoline, n	15